Clinical Trial Update: Inhaled Iloprost for Suspected COVID-19 Respiratory Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating inhaled iloprost for suspected COVID-19 respiratory failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoxemic Respiratory Failure
• Respiratory Distress Syndrome

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: COVID-19, ARDS, Human | Phase 2 | Status: COMPLETED